

## ICMJE DISCLOSURE FORM

**Date:** 3/7/2022

**Your Name:** Aleksander Krag

**Manuscript Title:** Ansvarshavende redaktør for Medicin.dk

**Manuscript Number (if known):** Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)																				
<b>Time frame: Since the initial planning of the work</b>																							
<b>1</b>	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<input checked="" type="checkbox"/> <b>None</b>  <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="height: 20px;"> </td><td style="width: 20%;"> </td></tr> <tr><td style="height: 20px;"> </td><td> </td></tr> <tr><td style="height: 20px;"> </td><td> </td></tr> </table>							<table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="height: 20px;"> </td><td style="width: 20%;"> </td></tr> <tr><td style="height: 20px;"> </td><td> </td></tr> <tr><td style="height: 20px;"> </td><td> </td></tr> </table> <p style="font-size: small; color: gray; text-align: right;">Click the tab key to add additional rows.</p>														
<b>Time frame: past 36 months</b>																							
<b>2</b>	Grants or contracts from any entity (if not indicated in item #1 above).	<input type="checkbox"/> <b>None</b>  <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="height: 20px;">EU Horizon 2020</td><td style="width: 20%;">Coordinator of Galaxy, EU funded under grant agreement No 668031</td></tr> <tr><td style="height: 20px;">EU Horizon 2020</td><td>PI in LiverScreen, EU funded under grant agreement No 847989</td></tr> <tr><td style="height: 20px;">EU Horizon 2020</td><td>PI in MicrobPredict, EU funded under grant agreement No 825694.</td></tr> <tr><td style="height: 20px;">EU Horizon 2020</td><td>PI in IHMCSA, EU funded under grant agreement No 964590</td></tr> <tr><td style="height: 20px;">Novo Nordisk Foundation</td><td>PI in MicrobLiver, A Challenge Grant, grant number NNF15OC0016692 from the Novo Nordisk Foundation</td></tr> <tr><td style="height: 20px;">Innovationfund Denmark</td><td>Research funding, Innoexplorer</td></tr> <tr><td style="height: 20px;">Danish National Research Foundation</td><td>PI in ATLAS, Centre of Excellence</td></tr> </table>	EU Horizon 2020	Coordinator of Galaxy, EU funded under grant agreement No 668031	EU Horizon 2020	PI in LiverScreen, EU funded under grant agreement No 847989	EU Horizon 2020	PI in MicrobPredict, EU funded under grant agreement No 825694.	EU Horizon 2020	PI in IHMCSA, EU funded under grant agreement No 964590	Novo Nordisk Foundation	PI in MicrobLiver, A Challenge Grant, grant number NNF15OC0016692 from the Novo Nordisk Foundation	Innovationfund Denmark	Research funding, Innoexplorer	Danish National Research Foundation	PI in ATLAS, Centre of Excellence	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="height: 20px;"> </td><td style="width: 20%;"> </td></tr> <tr><td style="height: 20px;"> </td><td> </td></tr> <tr><td style="height: 20px;"> </td><td> </td></tr> </table>						
EU Horizon 2020	Coordinator of Galaxy, EU funded under grant agreement No 668031																						
EU Horizon 2020	PI in LiverScreen, EU funded under grant agreement No 847989																						
EU Horizon 2020	PI in MicrobPredict, EU funded under grant agreement No 825694.																						
EU Horizon 2020	PI in IHMCSA, EU funded under grant agreement No 964590																						
Novo Nordisk Foundation	PI in MicrobLiver, A Challenge Grant, grant number NNF15OC0016692 from the Novo Nordisk Foundation																						
Innovationfund Denmark	Research funding, Innoexplorer																						
Danish National Research Foundation	PI in ATLAS, Centre of Excellence																						

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Region of Southern Denmark	Center grant for Elite Research Centre FLASH
<b>3</b>	Royalties or licenses	<input type="checkbox"/> <b>None</b>	
		Gyldendal	Medicinsk compendium, medforfatter
<b>4</b>	Consulting fees	<input checked="" type="checkbox"/> <b>None</b>	
<b>5</b>	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> <b>None</b>	
		Norgine	Lectures 2019, 2020
		Siemens	Lectures, speaker's bureau 2019, 2020
		Nordic Bioscience	Lecture 2021
<b>6</b>	Payment for expert testimony	<input checked="" type="checkbox"/> <b>None</b>	
<b>7</b>	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> <b>None</b>	
<b>8</b>	Patents planned, issued or pending	<input checked="" type="checkbox"/> <b>None</b>	
		Region of Southern Denmark	Biomarker - pending/planned
		University of Southern Denmark	Biomarker- pending/planned
<b>9</b>	Participation on a Data Safety	<input type="checkbox"/> <b>None</b>	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
	Monitoring Board or Advisory Board	Norgine Siemens Norgine	Advisory board meeting 2020 Advisory board meeting 2019, 2020 Advisory board meeting 2020						
<b>10</b>	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> <b>None</b>  <table border="1"> <tr> <td>Vice Secretary General European Association for the Study of The Liver (EASL)</td> <td>Non for profit organization and position without remuneration</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>		Vice Secretary General European Association for the Study of The Liver (EASL)	Non for profit organization and position without remuneration				
Vice Secretary General European Association for the Study of The Liver (EASL)	Non for profit organization and position without remuneration								
<b>11</b>	Stock or stock options	<input checked="" type="checkbox"/> <b>None</b>  <table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>							
<b>12</b>	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input type="checkbox"/> <b>None</b>  <table border="1"> <tr> <td>Norgine</td> <td>Rifaximin for an investigator initiated study, Galaxy EU funded under grant agreement No 847989</td> </tr> <tr> <td>Siemens</td> <td>ELF test for an investigator initiated study</td> </tr> <tr> <td>Echosence</td> <td>Fibroscan for an investigator initiated study, LiverScreen EU funded under grant agreement No 847989</td> </tr> </table>		Norgine	Rifaximin for an investigator initiated study, Galaxy EU funded under grant agreement No 847989	Siemens	ELF test for an investigator initiated study	Echosence	Fibroscan for an investigator initiated study, LiverScreen EU funded under grant agreement No 847989
Norgine	Rifaximin for an investigator initiated study, Galaxy EU funded under grant agreement No 847989								
Siemens	ELF test for an investigator initiated study								
Echosence	Fibroscan for an investigator initiated study, LiverScreen EU funded under grant agreement No 847989								
<b>13</b>	Other financial or non-financial interests	<input checked="" type="checkbox"/> <b>None</b>  <table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>							

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.